Trikafta and Kalydeco drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trikafta (elexacaftor, ivacaftor, tezacaftor; ivacaftor) and Kalydeco (ivacaftor). Common drug interactions include alanine aminotransferase increased among females and acute respiratory failure among males.

The phase IV clinical study analyzes what interactions people have when they take Trikafta and Kalydeco. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Trikafta?

Trikafta has active ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor. eHealthMe is studying from 11,852 Trikafta users. Check the latest studies of Trikafta.

What is Kalydeco?

Kalydeco has active ingredients of ivacaftor. eHealthMe is studying from 6,652 Kalydeco users. Check the latest studies of Kalydeco.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

23 people who take Trikafta and Kalydeco together, and have interactions are studied.

Trikafta and Kalydeco drug interactions.

What are the common drug interactions of Trikafta and Kalydeco, by gender? *:

female:

Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood lactate dehydrogenase increased
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Gamma-glutamyltransferase increased
Maternal exposure during pregnancy (use of substance during pregnancy)
Premature delivery
Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Pulmonary haemorrhage (acute bleeding from the lung)

male:

Acute respiratory failure
Blood bilirubin increased
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Dry eye (lack of adequate tears)
Gamma-glutamyltransferase increased
Abdominal discomfort
Exercise tolerance decreased
Forced expiratory volume decreased (decreased lung expired air volume)

What are the common drug interactions of Trikafta and Kalydeco, by age (0-1 to 60+)? *:

0-1:

Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Neonatal respiratory distress syndrome (a serious medical condition where a newborn baby's lungs cannot provide their body with enough oxygen)
Pulmonary haemorrhage (acute bleeding from the lung)
Premature baby

2-9:

n/a

10-19:

n/a

20-29:

Maternal exposure during pregnancy (use of substance during pregnancy)
Premature delivery

30-39:

Acute respiratory failure
Blood bilirubin increased
Generalised oedema (swelling all over the body)
Hyperbilirubinaemia (excess of bilirubin in the blood)
Hypotension (abnormally low blood pressure)
Lymphopenia (an abnormally low level of lymphocytes in the blood)
Neutropenia (an abnormally low number of neutrophils)
Pneumonia
Rash erythematous (redness of the skin)
Thrombocytopenia (decrease of platelets in blood)

40-49:

Abdominal discomfort
Exercise tolerance decreased
Forced expiratory volume decreased (decreased lung expired air volume)
Hepatic necrosis (large portions of liver die off due to severe liver disease)
Respiratory disorder (respiratory disease)
Weight decreased
Hepatitis (inflammation of the liver)
Death
Haemoglobin decreased
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

50-59:

Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood lactate dehydrogenase increased
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Gamma-glutamyltransferase increased

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 20 people, 86.96%
Infection: 7 people, 30.43%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 7 people, 30.43%
Reflux Gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile): 6 people, 26.09%
Cystic Fibrosis Related Diabetes: 6 people, 26.09%
Bronchial Hyperreactivity: 6 people, 26.09%
Hepatic Necrosis (large portions of liver die off due to severe liver disease): 4 people, 17.39%
Respiratory Tract Infection: 3 people, 13.04%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 13.04%
Fever: 3 people, 13.04%

* Approximation only. Some reports may have incomplete information.

Do you take Trikafta and Kalydeco?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously